FDA Approved Hovilpri for Herpes Simplex Lesions
The new drug provides a treatment option for immunocompromised adults with lesions unresponsive to traditional antivirals.
Updated on Oct. 9, 2026 in Cancer
Live Poll
Do you trust the FDA's current process for evaluating the safety and effectiveness of new drugs?
The FDA has granted approval for Hovilpri tablets, a treatment specifically designed for immunocompromised adults suffering from herpes simplex virus (HSV) lesions. This medication is indicated for patients who have shown no improvement when using standard antivirals like acyclovir, valacyclovir, or famciclovir.
Why it matters
Immunocompromised patients frequently face persistent HSV outbreaks that fail to clear with standard therapy, leaving a significant clinical gap. Hovilpri offers a new path to healing for this vulnerable population.
In the 101-patient PRIOH-1 trial, 63% of patients achieved total lesion healing within 28 days using Hovilpri, compared to 34% in the group using comparator medications.
The players
Food and Drug Administration
The United States federal agency responsible for regulating food, drugs, and medical devices to ensure public health safety.
The details
Hovilpri is administered to patients for a primary period of 28 days, which can be extended up to 42 days for those who show signs of lesion improvement. The drug, which received priority review, lists headache as its most common adverse reaction.
Timeline
The FDA approved Hovilpri tablets on October 9, 2026.
Deeper Dive
This approval follows the established FDA pathway for priority review of therapies addressing significant unmet clinical needs.
Patients with persistent, resistant lesions may now consult their healthcare providers about Hovilpri as an alternative to ineffective standard antivirals. Those prescribed the medication should monitor for headaches, which were identified as the most common side effect in trials.
The takeaway
The arrival of Hovilpri provides a crucial second-line defense for patients whose immune systems struggle to fight off common viral outbreaks. Physicians now have a clinically validated option to address cases that were previously unresponsive to conventional drugs.
Further reading
Learn more about the latest developments in medical treatments on the United States Cancer page.
More information
Review the full details in the FDA drug approval announcement.
Live Poll
Do you trust the FDA's current process for evaluating the safety and effectiveness of new drugs?
